Vunakizumab in moderate-to-severe chronic plaque psoriasis: a profile of its use

Vunakizumab (安达静®), a novel anti-IL-17A humanised IgG1/k monoclonal antibody, is a new and efficacious treatment option for patients with moderate-to-severe chronic plaque psoriasis. It has been approved in China in this indication in adults who are candidates for systemic therapy or phototherapy. In a pivotal phase 3 trial, vunakizumab significantly increased the proportions of patients who achieved reductions in the extent and severity of psoriasis, and complete or near complete clearance of psoriasis at week 12 of treatment compared with placebo. Additionally, vunakizumab improved quality of life compared with placebo. Complete or near complete clearance of symptoms and lesions was maintained in the majority of patients through to week 52. Vunakizumab was generally well tolerated through the 12-week induction therapy period. No new safety signals were reported in the maintenance therapy period through to week 52. Chronic plaque psoriasis is an inflammatory skin condition that can cause a substantial reduction in a patient’s quality of life. Vunakizumab (安达静®) is a new treatment that blocks one of the key inflammatory cascades that leads to chronic plaque psoriasis. It is approved in China for adults with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. In a pivotal phase 3 study, complete or near complete clearance of chronic plaque psoriasis symptoms and lesions occurred significantly more frequently in vunakizumab than placebo recipients at week 12 of treatment, and treatment response was maintained in the majority of vunakizumab recipients through to week 52. Vunakizumab was also generally well tolerated through to week 52. Therefore, vunakizumab represents a new and efficacious treatment option for patients with moderate-to-severe chronic plaque psoriasis.